{"id":27699,"date":"2019-07-29T14:59:00","date_gmt":"2019-07-29T12:59:00","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=27699"},"modified":"2025-01-29T13:51:29","modified_gmt":"2025-01-29T12:51:29","slug":"july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo","status":"publish","type":"post","link":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/","title":{"rendered":"July 29, 2019<\/span> | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO"},"content":{"rendered":"

Corporate news<\/h1>\n

to the archive<\/a><\/p>\n

Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO<\/h1>\n

Gr\u00fcnwald, July 29, 2019 \u2013 The Supervisory Board of Dermapharm Holding SE (\u201cDermapharm\u201d) has announced a change in the composition of the Management Board. The current Chief Marketing Officer Stefan Grieving will be leaving the company for health reasons on July 31, 2019. Dr. J\u00fcrgen Ott to succeed him as of October 1, 2019.<\/strong><\/p>\n

\u201cWe would like to thank Mr. Grieving for his longstanding commitment to Dermapharm. Over the past nine years, he has played a key role in shaping our company\u2019s positive development and we have come to value him as a competent and loyal colleague. We wish him all the best for the future! In Dr. J\u00fcrgen Ott, we have now found a suitable successor as Chief Marketing Officer who, due to his extensive experience in the consumer goods and pharmaceutical industries, fits very well with Dermapharm,\u201d explained Wilhelm Beier, Chairman of the Supervisory Board of Dermapharm Holding SE.<\/p>\n

Dr. J\u00fcrgen Ott (51) has many years of experience in the marketing and sales sectors and will be responsible for both sales and marketing in his function as a member of the Dermapharm Management Board. His last position since 2010 was Head of Marketing Germany, since 2014 Head of Marketing & Sales Germany and from 2017 Regional Head Central Europe at Bionorica SE, a manufacturer of herbal pharmaceuticals. In particular, Dr. Ott brings valuable experience to the range of herbal products, which Dermapharm wants to further develop.<\/p>\n

\u201cI am very much looking forward to my tasks at Dermapharm,\u201d explained Dr. J\u00fcrgen Ott. \u201cTogether with my colleagues, we will set important impulses for the optimal further development of the range of herbal products as part of our growth strategy and further expand Dermapharm\u2019s position as a leading pharmaceutical manufacturer in selected markets.\u201d<\/p>\n

Post as PDF<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Gr\u00fcnwald, July 29, 2019 \u2013 The Supervisory Board of Dermapharm Holding SE (\u201cDermapharm\u201d) has announced a change in the composition of the Management Board. The current Chief Marketing Officer Stefan Grieving will be leaving the company for health reasons on July 31, 2019. Dr. J\u00fcrgen Ott to succeed him as of October 1, 2019.<\/p>\n","protected":false},"author":2,"featured_media":98872,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[215,90],"tags":[260],"class_list":["post-27699","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-corporate-news-en","category-news-en","tag-2019-2"],"acf":[],"yoast_head":"\nJuly 29, 2019 | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO - cometis AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"July 29, 2019 | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO\" \/>\n<meta property=\"og:description\" content=\"Gr\u00fcnwald, July 29, 2019 \u2013 The Supervisory Board of Dermapharm Holding SE (\u201cDermapharm\u201d) has announced a change in the composition of the Management Board. The current Chief Marketing Officer Stefan Grieving will be leaving the company for health reasons on July 31, 2019. Dr. J\u00fcrgen Ott to succeed him as of October 1, 2019.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-29T12:59:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T12:51:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"171\" \/>\n\t<meta property=\"og:image:height\" content=\"31\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\"},\"headline\":\"July 29, 2019 | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO\",\"datePublished\":\"2019-07-29T12:59:00+00:00\",\"dateModified\":\"2025-01-29T12:51:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/\"},\"wordCount\":317,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"keywords\":[\"2019\"],\"articleSection\":[\"Dermapharm Corporate News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/\",\"name\":\"July 29, 2019 | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO - cometis AG\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"datePublished\":\"2019-07-29T12:59:00+00:00\",\"dateModified\":\"2025-01-29T12:51:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"width\":172,\"height\":172},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2019\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/tag\\\/2019-2\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"July 29, 2019 | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cometis-ag\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/cometisAG\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/author\\\/assistenz-cometis-ag\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"July 29, 2019 | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO - cometis AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/","og_locale":"en_US","og_type":"article","og_title":"July 29, 2019 | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO","og_description":"Gr\u00fcnwald, July 29, 2019 \u2013 The Supervisory Board of Dermapharm Holding SE (\u201cDermapharm\u201d) has announced a change in the composition of the Management Board. The current Chief Marketing Officer Stefan Grieving will be leaving the company for health reasons on July 31, 2019. Dr. J\u00fcrgen Ott to succeed him as of October 1, 2019.","og_url":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/","og_site_name":"cometis AG","article_published_time":"2019-07-29T12:59:00+00:00","article_modified_time":"2025-01-29T12:51:29+00:00","og_image":[{"width":171,"height":31,"url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/#article","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1"},"headline":"July 29, 2019 | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO","datePublished":"2019-07-29T12:59:00+00:00","dateModified":"2025-01-29T12:51:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/"},"wordCount":317,"publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"image":{"@id":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","keywords":["2019"],"articleSection":["Dermapharm Corporate News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/","url":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/","name":"July 29, 2019 | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO - cometis AG","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/#primaryimage"},"image":{"@id":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","datePublished":"2019-07-29T12:59:00+00:00","dateModified":"2025-01-29T12:51:29+00:00","breadcrumb":{"@id":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/#primaryimage","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","width":172,"height":172},{"@type":"BreadcrumbList","@id":"https:\/\/www.cometis.de\/en\/july-29-2019-dermapharm-holding-se-dr-juergen-ott-named-new-cmo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cometis.de\/en\/"},{"@type":"ListItem","position":2,"name":"2019","item":"https:\/\/www.cometis.de\/en\/tag\/2019-2\/"},{"@type":"ListItem","position":3,"name":"July 29, 2019 | Dermapharm Holding SE: Dr. J\u00fcrgen Ott named new CMO"}]},{"@type":"WebSite","@id":"https:\/\/www.cometis.de\/en\/#website","url":"https:\/\/www.cometis.de\/en\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cometis.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cometis.de\/en\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/www.cometis.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/cometis-ag\/","https:\/\/www.youtube.com\/user\/cometisAG"]},{"@type":"Person","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/www.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/27699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=27699"}],"version-history":[{"count":0,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/27699\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media\/98872"}],"wp:attachment":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=27699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=27699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=27699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}